Attributional Style and Adherence to Hydroxyurea in Adults with Sickle Cell Disease (HU Adherence Study)
Investigating Hydroxyurea adherence in adult SCD patients, Clinical Psychology Ph.D. candidate Lance Archer's study seeks to improve interventions.
18 to 65
Survey
Yes
N/A
All types of SCD
United States and Canada
Exercise Collapse Associated with Sickle Cell Trait (ECAST)
Sickle cell trait study to determine which sickle cell trait carriers are at risk for Exercise Collapse Associated with Sickle Cell Trait (ECAST).
18 to 45
Other
Yes
N/A
Hb AS - sickle cell trait
US participation only
KNOWledge and Understanding of Sickle Cell Trait (KNOWUrSCT): A Global Health Disparity Research Study
This study aims to explore perceptions of sickle cell trait (SCT), SCT testing, understand related complications/experiences, and develop community-driven resources for SCT.
18 years or older
Survey
Yes
N/A
Open to everyone
Global & Remote
ASCENT1 Study
A research study investigating how well NDec works in people with sickle cell disease.
18 years or older
Clinical
Yes
2
SCD type SS
SCD type SC
SCD type Sβ0 thalassemia
....
US
Canada
An Electronic Patient Reported Pain Assessment in Sickle Cell
A study that aims to gather insights into painful crises in people living with sickle cell disease.
18 years or older
Digital
Yes
N/A
SCD type SS
SCD type Sβ0 thalassemia
USA
Hibiscus Study: An oral investigational medication for SCD
The Hibiscus Study is enrolling adults and adolescents 12 to 65 years old with a clinical diagnosis of SCD. The primary purpose of the study is to evaluate the safety and effect...
12 to 65
Clinical
Yes
2/3
All types of SCD
17 Nov 2023
Health authorities in the U.K. on Thursday approved a new kind of medicine that uses CRISPR gene editing to treat the blood diseases sickle cell and beta thalassemia, marking it the first time a drug built with the Nobel Prize-winning technology has won regulatory clearance anywhere in the world.
Learn more
17 Nov 2023
Doctor Peter Lin will tell us about a groundbreaking new treatment that uses gene-editing…with the potential to cure a serious blood disorder. And it could soon get the greenlight for use in the U-S.
Learn more
16 Nov 2023
The United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional marketing authorization for CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited therapy, for the treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT)
Learn moreWe send occasional updates that feature new trials, and other great tips. We will not spam you.
